Evidence map›Paper›PMID 39991674›Full record

ArticleWorld journal of gastroenterology2025

Modified

Yi-Tong Qiu, Xin-Yi Luo, Ya-Feng Deng, Xue Zheng, Jian-Guo Qiu, Lin-Sheng Zhang, Xiao-Qi Huang, Xue-Bao Zheng, Hai-Yang Huang

Abstract read
In one paragraph

Article in World journal of gastroenterology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Article
  2. The Brown Strain ofInternational journal of molecular sciences · 2026
    Article
  3. Review
  4. Article
  5. Review
  6. The Protective Effects ofFood science & nutrition · 2025
    Article
  7. New insights into the mechanisms of modifiedWorld journal of gastroenterology · 2025
    Article
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Yi-Tong QiuSchool of Pharmaceutical Sciences, Guangzhou University of Chinese Medicine, Guangzhou 525000, Guangdong Province, China.
Xin-Yi LuoSchool of Pharmaceutical Sciences, Guangzhou University of Chinese Medicine, Guangzhou 525000, Guangdong Province, China.
Ya-Feng DengSchool of Pharmaceutical Sciences, Guangzhou University of Chinese Medicine, Guangzhou 525000, Guangdong Province, China.
Xue ZhengSchool of Pharmaceutical Sciences, Guangzhou University of Chinese Medicine, Guangzhou 525000, Guangdong Province, China.
Jian-Guo QiuSchool of Pharmaceutical Sciences, Guangzhou University of Chinese Medicine, Guangzhou 525000, Guangdong Province, China.
Lin-Sheng ZhangSchool of Pharmaceutical Sciences, Guangzhou University of Chinese Medicine, Guangzhou 525000, Guangdong Province, China.
Xiao-Qi HuangSchool of Pharmaceutical Sciences, Guangzhou University of Chinese Medicine, Guangzhou 525000, Guangdong Province, China.
Xue-Bao ZhengSchool of Pharmaceutical Sciences, Guangzhou University of Chinese Medicine, Guangzhou 525000, Guangdong Province, China.
Hai-Yang HuangInstitute of Traditional Chinese Medicine, Dongguan Hospital of Traditional Chinese Medicine, Dongguan 523000, Guangdong Province, China. 514234458@qq.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundModified

aimTo investigate the therapeutic effect and mechanism of modified PD in IM.

methodsThis study used an IM mouse model established using 5-fluorouracil injections to investigate the effects of the modified PD (3, 6, and 12 g/kg) in IM. The primary chemical components of the modified PD were identified using liquid chromatography-mass spectrometry. Body weight loss, diarrhea scores, intestinal length, histopathological scores, and inflammatory cytokine levels were measured to evaluate the effects of the modified PD in IM. Effects on the TLR4/MyD88/NF-κB pathway were evaluated using western blot analysis. The intestinal microbiota was characterized using Illumina NovaSeq sequencing.

resultsThe results showed that modified PD significantly improved weight loss and diarrhea and shortened the intestines in IM mice. Mechanistically, modified PD suppressed the TLR4/MyD88/NF-κB pathway and downregulated the expression of reactive oxygen species, lipopolysaccharides, and pro-inflammatory cytokines (IL-1β, TNF-α, IFN-γ, IL-6, IL-8, and IL-17), while increasing the expression of the anti-inflammatory cytokine IL-10. Furthermore, modified PD protected the intestinal mucosal barrier by increasing the expression of tight junction proteins (occludin-1, claudin-1, and ZO-1) and mucin-2. Finally, 16S rDNA sequencing revealed that modified PD improved intestinal dysbiosis.

conclusionOur research offers new insights into the potential mechanism of modified PD in alleviating IM and provides experimental evidence supporting its pharmaceutical application in clinical IM treatment.

Indexed as

Drugs, Chinese HerbalGastrointestinal MicrobiomeIntestinal MucosaMucositisPulsatillaAnimalsCytokinesDisease Models, AnimalFluorouracilHumansMaleMiceMyeloid Differentiation Factor 88NF-kappa BSignal TransductionToll-Like Receptor 4CytokinesDrugs, Chinese HerbalFluorouracilMyd88 protein, mouseMyeloid Differentiation Factor 88NF-kappa BTlr4 protein, mouseToll-Like Receptor 4Gut microbiota, TLR4/MyD88/NF-κB pathwayInflammatory responseIntestinal mucositisModified Pulsatilla decoctionOxidative stress

Identifiers

PMID39991674
PMCPMC11755253

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.